Welcome to our dedicated page for Black TITAN SEC filings (Ticker: BTTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Black Titan Corporation (NASDAQ: BTTC) SEC filings page on Stock Titan is intended to centralize access to the company’s regulatory disclosures once they are available through the EDGAR system. While no specific filings are listed in the current data, investors typically look to this type of page for documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, registration statements, and beneficial ownership or insider trading reports on forms like Form 3 and Form 4.
For a company such as Black Titan, which has publicly described a strategic focus on digital assets and blockchain and has introduced the Digital Asset Treasury Plus (DAT+) framework, SEC filings can provide additional context on risk factors, business strategy, and how digital asset activities are reflected in financial statements and disclosures. Filings may also describe the impact of transactions such as the merger in which Titan Pharmaceuticals, Inc. became a wholly owned subsidiary of Black Titan Corporation and the combined company’s shares began trading on Nasdaq under the BTTC symbol.
On Stock Titan, new SEC filings for BTTC are captured from EDGAR and presented in a chronological list. Each filing can be opened for full text review, and AI-powered tools summarize the key points in accessible language, helping readers understand complex sections such as risk factor discussions, management’s analysis, and detailed footnotes. Over time, this page will serve as a structured record of Black Titan’s regulatory reporting, supporting research into its digital asset strategy, corporate structure, and governance disclosures.
Black Titan Corporation is registering up to 5,917,484 ordinary shares for resale by existing shareholders. These consist of 2,344,100 shares issued as merger consideration, 1,474,530 shares issuable upon conversion of Series A preferred shares, 176,470 shares from Series C preferred conversion, 9,563 shares including 6,250 underlying options for a director, 512,820 shares issued under an October 30, 2025 settlement, and 1,400,001 shares to be issued to three advisory service providers.
The company will not receive proceeds from resale of these shares, other than any cash paid if the 6,250 options are exercised. Those options have exercise prices of $30.40 and $26.20 per share, while the ordinary share price was $2.75 on December 12, 2025, so the prospectus notes exercises are currently unlikely. As of the prospectus date, 9,086,610 ordinary shares were outstanding, trading on Nasdaq under the symbol “BTTC.”
Black Titan, a Cayman Islands company, was formed in 2024 and completed a business combination on October 1, 2025, acquiring Titan Pharmaceuticals, Inc. and Malaysian HCM software distributor TalenTec. The prospectus cautions that resale of this substantial block of shares, or expectations of such sales, could increase volatility or lead to a significant decline in the trading price.
FAQ
What is the current stock price of Black TITAN (BTTC)?
What is the market cap of Black TITAN (BTTC)?
